Tango Therapeutics, Inc. 4

Director Mace Rothenberg received 4,000 RSU-based common shares and 25,000 stock options of Tango Therapeutics, Inc. as equity compensation on June 5, 2026.

On June 5, 2026, director Mace Rothenberg of Tango Therapeutics, Inc. received an equity compensation package consisting of 4,000 shares of common stock in the form of restricted stock units (RSUs) that vest in full on the earlier of June 5, 2027 or the next annual stockholders’ meeting, and a stock option grant for 25,000 shares of common stock at an exercise price of $20.22 per share vesting in 12 equal monthly installments starting July 5, 2026, all in connection with his board service. Following these awards, Rothenberg directly beneficially owns 41,500 shares of common stock and 25,000 stock options, representing a meaningful but routine director compensation grant with no open-market purchase or sale activity reported in this filing.

Filing Facts

CIK

1819133

Ticker

TNGX

Form

4

Source Type

sec

Accession

0001193125-26-262191

Alert Tier

5